222 Users Online
Single Domain Antibody Platforms Market Segmented By Multi-specific, Bispecific, Multivalent, Mono-specific Type from Camelids, Sharks Animal Source
The global single domain antibody platforms market was valued at US$ 23.8 Mn at the end of 2021, with an estimated CAGR of 10.6% for the next ten years to reach US$ 72.6 Mn at the end of 2032.
Single domain antibodies used in pharmaceutical and biotechnology companies held a market value of US$ 9.3 Mn in 2021, accounting for over 39% of the overall market share. Single domain antibody platforms market accounted for 6.1% share of the global custom antibody market in 2021.
Single Domain Antibody Platforms Market Size (2022)
US$ 26.4 Mn
Projected Market Value (2032)
US$ 72.6 Mn
Global Market Growth Rate (2022-2032)
Market Share of Top 5 Countries
The global single domain antibody platforms market expanded at a CAGR of 8.9% over the last six years (2015-2021).
Increasing incidence of immune disorders, viral infections, and cancer is leading to the rising demand for innovative treatments to achieve better results, which, in turn, is fuelling revenue growth of single domain antibody platforms.
Thus, single domain antibodies used for the discovery and development of biologic-based drugs for the treatment of cancer will drive market growth over the coming years.
R&D investments are also anticipated to increase across the world, which will bolster the growth of the market.
Top market players are concentrating on the creation and introduction of innovative immunotherapies using single domain antibodies to treat different cancer types and infectious disorders. The need for single domain antibody-based therapies is rising as a result of the increased acceptance of novel therapeutics, which is expected to fuel the market for single domain antibody platforms as well.
The global single domain antibody platforms market is predicted to surge ahead at a CAGR of 10.6%, with recorded sales expected to reach US$ 72.6 Mn by the end of 2032.
“Rising Use of Single Domain Antibodies in Drug Development and Development of New Cancer Treatment”
Rapidly increasing collaborative activities by single domain antibody service provider companies with research institutes, biopharmaceutical companies, and clinical research organizations (CROs) are expected to propel the market growth over the forecast period. Market players are entering into collaborations to develop and upgrade key healthcare technologies as well as develop new products and services.
Additionally, prioritizing developing nations and raising R&D expenditures will accelerate market expansion. The potential for outsourcing biotech projects has increased by the availability of skilled labor in developing nations such as China and India, at affordable prices.
“Stringent Regulatory Approvals, Lack of Skilled Professionals, & High Maintenance of Antibodies”
As biologics progress through commercialization and clinical trials, regulatory requirements will become more and more stringent. The approval of biological products in the U.S. requires a Biologics License Application (BLA).
The product, as well as the process, must be validated and exclusively monitored against critical quality attributes (CQAs) throughout the manufacturing process.
Regulatory bodies must approve not only the end product but also the process, CQAs, antibodies, consumable cell lines, and equipment that went into production, to gain approval. The long times associated with waiting for regulatory approvals will hamper the growth of the single domain antibody platforms market to some extent.
Camelid species may not be readily available to all researchers and animal husbandry because it necessitates specialized facilities. It is necessary to utilize more than one animal and analyze the consistency of particular immunization processes, such as DNA immunization, to avoid the heterogeneity of immune responses. This can be a key challenge to maintain process efficiency and is a major restraint to market growth.
The handling of recombinant antibodies required specialized laboratory training. Additionally, lack of experience in research laboratories has hampered the growth of the single domain antibody platforms market due to inadequate practice in handling recombinant antibodies.
Unfortunately, there is a shortage of qualified experts working in research and development. Low pay ranges, difficult roles, and insufficient laboratory training are all contributing factors to the shortage of trained experts.
Why are Single Domain Antibody Platform Manufacturers Targeting the U.S.?
“Growing Cancer Prevalence & Focus on Enhanced Treatment Options”
In 2022, the U.S. is estimated to account for a market share of more than 86% in the North American single domain antibody platforms market.
These figures indicate the rising incidence of cancer and the increase in research and development of new drugs to develop better treatment options in the country.
How is Demand for Single Domain Antibodies Shaping Up in Germany?
“High Level of Research Activities Ongoing in Germany”
Germany is projected to account for 30.8% of Europe's single domain antibody platforms market share in 2022 and is projected to exhibit steady growth at a CAGR growth rate of 10.5% through 2032.
The German market for single domain antibody platforms is being propelled by new molecular technologies that could rapidly diagnose infectious diseases or cure diseases such as cancer with better diagnostic tools and immune therapies.
Moreover, Germany holds the largest market share in Europe due to the presence of many major players in the country, which also increases the accessibility of products in the country.
Why is China Emerging as a Prominent Market for Single Domain Antibody Platforms?
“Increasing Strategic Collaborations and Agreements”
In 2022, the China single domain antibody platforms market is estimated to be valued at US$ 1.5 Mn with a market share of 46.6% in the East Asia single domain antibody platforms market.
Several market players are focusing on expansion through global agreements for commercialization, thus contributing to market growth in China.
Such agreements would drive the Chinese market and will offer lucrative opportunities for local manufacturers.
What is the Outlook for India Regarding Single Domain Antibody Platforms?
“Newer Policy Announcement for Business Expansion”
India will account for 37.8% market share of the total value of the South Asia single domain antibody platforms market and reach US$ 0.9 Mn in 2022.
India, a developing country in the South Asian region, has announced government policies for new start-up companies as well as for MNCs across domains, including biotechnology. As per these policies, start-up companies in India are exempted from tax for the first three years after establishment, and the costs for patent protection are subsidized.
Thus, favorable government policies are expected to drive demand for single domain antibody platforms in India.
Which Platform Type of Single Domain Antibodies Accounts for High Market Growth?
“High Demand for Bispecific Single Domain Antibodies”
The multispecific single domain antibody segment, among other platform types, will account for the highest market share of 31.7% by revenue in 2022, followed by the bispecific single domain antibody platform type at a growth rate of 9.4% in 2022.
Multi-specific single domain antibodies bind multiple targets (more than one) with one nanobody molecule and target two or more antigens. Due to this factor, the segment accounts for the increasing demand for multispecific single domain antibodies.
Which Animal Sources are Widely Used for Single Domain Antibodies?
“Camelid Antibodies Dominate among Other Animal Sources”
Camelids antibodies are projected to dominate the market with a revenue share of 91.6% in 2022.
Camelid antibodies are much smaller in size and can detect various epitopes with minimum steric hindrance, powering the growth of this segment.
Which Application of Single Domain Antibodies is Most Popular?
“Therapeutic Development Continues to Account for Highest Market Share”
Therapeutic development will hold the highest market share of around 45% in 2022 and is projected to dominate over the forecast period as an application, with a growth rate of 10.3% CAGR.
Single domain antibodies are highly effective in immune therapy, cancer treatment, and anti-viral therapy. Thus, innovative cancer treatment methods and high demand for adopting single domain antibodies in drug development will lead to rapid segment growth.
Leading single domain antibody platform providers are aiming at collaborations and accreditation to drive their product demand and sales footprint across countries. Single domain antibody manufacturers are focused on innovative drug development and product patenting for gaining high market revenue.
Similarly, recent developments related to companies manufacturing single domain antibody platforms have been tracked by the team at Persistence Market Research, which are available in the full report.
Historical Data Available for
US$ Million for Value
Key Countries Covered
Key Market Segments Covered
Key Companies Profiled
Customization & Pricing
Available upon Request
Single Domain Antibody Platforms Market by Platform Type:
Single Domain Antibody Platforms Market by Animal Source:
Single Domain Antibody Platforms Market by Application:
Single Domain Antibody Platforms Market by End User:
Single Domain Antibody Platforms Market by Region:
The global single domain antibody platforms market was valued at US$ 23.8 Mn in 2021 and is expected to expand at 10.6% CAGR through 2032.
The single domain antibody platform industry is set to reach US$ 72.6 Mn by 2032.
The market expanded at 8.9% CAGR from 2015 to 2021, owing to the expansion of pharmaceutical and biotechnology industries.
Key market players are GenScript Biotech Corporation, Kaneka Eurogentec S.A, and Creative BioLabs.
Increasing consolidation activities among key players and customized service offerings for specific needs are key trends in this industry.
The multi-specific single domain antibody segment will hold 31.7% market share in 2022.
The U.S., Germany, China, U.K., and Canada account for the highest demand for single domain antibodies.
The U.S. accounts for more than 86% of the North American market share in 2022 and is expected to expand at a value CAGR of 11.7%.
The Europe single domain antibody platforms market is expected to record a CAGR of 9.7% over the decade.
China is expected to hold 46.6% share of the East Asian single domain antibody platforms market in 2022, whereas India is set to account for around 37.8% of the South Asian market share.